The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- BMC cancer
- Publicado em
- 5 mar 2025
- Citações
- 15
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis
Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Marie Gadaevi, Azade Ismayilova et al.
Descritores MeSH
- Glioblastoma
- Brain Neoplasms
- Temozolomide
- Antineoplastic Agents, Alkylating
- Progression-Free Survival
- Humans
- Chemotherapy, Adjuvant
Veja também
Estudos relacionados
- Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis
- Short-course radiotherapy with or without temozolomide in elderly patients with newly diagnosed glioblastoma: a time-to-event meta-analysis of overall and progression-free survival
- Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis
- Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma